Skin Substitute Patents: Top Companies & Filing Trends 2026
- Concentrated at the top. the five most active filers hold 44.6% of all 175 records in scope, and the ten most active hold 65.1% — a long tail of single- and low-count filers fills the rest.
- Filing kept climbing through 2024. annual filings rose 23% from 2021 (13) to 2024 (16), with 2022 the peak year so far at 18; 2025-2026 counts are still filling in due to publication lag.
- Sterilising and disinfecting claims dominate. A61L appears on 66.9% of records, well ahead of medicinal preparations (40.6%) and implants/prostheses (34.9%), signalling where claim space is most occupied.
Filing growth compares 2021 (13 records) with 2024 (16) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 175 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape maps 175 published records matching skin substitute and regenerative wound matrix terminology, filtered against acellular dermal matrix, vascularization rate, graft take, storage, handling, cost effectiveness and chronic wound indication language in title and claims. The scope spans 2015 through the July 2026 data cut-off, capturing both foundational acellular matrix patents and more recent composite dressing and hair follicle neogenesis filings. Patent families, not raw document counts, are used for the assignee ranking, which neutralises continuation filings and multi-jurisdiction duplicates.
Reading the data this way surfaces where claim density already crowds a sub-area versus where filing activity is thin enough that a well-drafted first claim could still stake meaningful ground.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 175-record dataset: filings by year, and the IPC subclasses those filings carry.
Filing trend, 2017-2026
Annual filings ran from 17 in 2017 to a peak of 18 in 2022, then 16 in 2024 — a 23% rise over the 2021-2024 span. 2025 and 2026 show far fewer records only because publication lags filing by roughly 18 months; those years are not yet complete and should not be read as a slowdown.
Technology composition by IPC subclass
A61L (sterilising & disinfecting) appears on 66.9% of the 175 records, ahead of A61K medicinal preparations (40.6%), A61F implants & prostheses (34.9%) and C12N microorganisms & genetic engineering (26.9%). Because records can carry multiple classes, these shares sum to well over 100% — each is a share of the same 175-record base, not of each other.
Shares are the percentage of the 175 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Skin Substitutes and Regenerative Wound Care with Eureka
This page is one run against one query. Ask Eureka your own question about skin substitutes and regenerative wound care and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative recent filing
Acellular skin substitute for breast reconstruction and preparation method therefor (US20240131230A1)
Filed by L&C BIO CO., LTD. and published 2024-04-25, this filing describes an acellular skin substitute prepared without proteolytic enzymes or surfactants during acellularization, then cut to size with CNC machining against a design template for breast reconstruction implant coverage — aimed at reducing surgery time and seroma incidence by eliminating dead space after suturing.Abstract text is drawn directly from the published filing.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5667961A | Skin substitute | 54 |
| 2 | US5639654A | Process for creating a skin substitute and the resulting skin substitute | 53 |
| 3 | WO2011160055A2 | Hair follicle neogenesis | 35 |
| 4 | US20120022472A1 | Application method of external dermatological medications, evaluating method of the same, application evaluat… | 24 |
| 5 | US20180085486A1 | Multifunctional composite skin or wound dressing as regenerative skin substitute | 20 |
| 6 | US20110171180A1 | Bioengineered skin substitutes | 19 |
| 7 | US20190002836A1 | Method for Manufacturing Body Substitutes by Additive Deposition | 18 |
| 8 | US20090232878A1 | Artificial Skin Substitute | 18 |
| 9 | JP1989008974A | Production of skin substitute and obtained skin substitute | 17 |
| 10 | US7815931B2 | Artificial skin substitute | 14 |
Citation counts favour older filings that have had more time to accumulate citations within the searched corpus — treat them as a signal of influence, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for R&D and IP strategy
Three patterns stand out once filing counts, citations and technology classes are read together.
A crowded top, a thin tail
The leader alone accounts for 32 of the 175 records, with the fifth-ranked filer at 11 and the tenth at 6. That drop-off from leader to fifth place is steep, meaning most of the 49 ranked assignees hold only a handful of families each.
Sterilising and disinfecting is the busiest class
Two-thirds of records touch A61L, the sterilising and disinfecting subclass, well ahead of medicinal preparations and implant classes. New filings that only restate sterilisation or storage-stability claims are entering the densest part of the map.
Growth held through the last complete year
Filings rose from 13 in 2021 to 16 in 2024, a 23% increase, with 2022 marking the peak at 18. Because publication lags filing by about 18 months, 2025-2026 figures understate true activity and should not be read as a decline.
Foundational skin substitute patents still anchor the field
The two most-cited records in this dataset are early foundational skin substitute filings, each cited over 50 times. High citation counts here reflect age and prior-art influence within the searched corpus rather than current filing priority.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to skin substitutes and regenerative wound care, with the prior art for and against each one.
Who is filing, and where activity is thin
The leader board is dominated by a small group of specialist and diversified filers, but recent-year momentum has cooled across nearly all of them, and several claim sub-areas remain sparsely covered.
One filer well ahead of the field
The leading assignee holds 32 of the 175 records in scope, nearly triple the fifth-placed filer's count of 11. That gap suggests a dominant early-mover position built up over multiple filing years rather than a recent surge.
One collaboration stands out
Only 10 co-assignee pairs appear across the dataset, and one pair — a company and its affiliated entity — accounts for 9 shared filings, far more than any other pairing. Most other collaboration in this space is limited to two or three shared records.
Recent-year activity has gone quiet among top filers
Every named leader in the recent-momentum data shows zero or one filing in the latest year, including the overall leader. This is consistent with publication lag rather than an actual pullback, but it means the most recent competitive picture is not yet visible in the granted or published record.
| Assignee | Recent year | YoY |
|---|---|---|
| Coloplast A/S | 1 | — |
| Stratatech Corp | 0 | — |
| Shiseido Co., Ltd. | 0 | — |
| Kerecis hf | 0 | — |
| DATT LIFE SCI PVT LTD | 0 | — |
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | 0 | — |
| DATT MEDIPRODS | 0 | — |
| CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying a filing gap.
Check freedom-to-operate against the leader's portfolio
With one filer holding 32 of 175 records, any new acellular dermal matrix or graft-take product should be checked against that portfolio's claim scope before development proceeds far.
Explore assignee portfolios in EurekaProbe the under-claimed sub-areas
C12Q enzyme/DNA assay claims and A01M pest-control interactions sit well below the core A61L and A61K classes in record count, suggesting room for a first claim with less prior art to design around.
Run a white-space search in EurekaTrack the 2025-2026 publication gap
Because publication lags filing by roughly 18 months, the current 2025-2026 filing counts will keep rising. Re-checking this trend in six to twelve months will reveal whether the 2021-2024 growth pattern held.
Set a filing alert in EurekaFrequently asked questions
One assignee leads the ranked list with 32 of the 175 records in scope, well ahead of the fifth-ranked filer at 11 and the tenth at 6. The top five filers combined account for 44.6% of all records, and the top ten for 65.1%, so the field is concentrated at the top with a long tail of smaller filers behind it. This concentration matters for freedom-to-operate checks: a new entrant's first diligence step should be the leader's portfolio, not the full 49-company ranked list.
Filings grew 23% from 13 in 2021 to 16 in 2024, with 2022 marking the highest single year so far at 18 filings. The apparent drop in 2025 and 2026 is a publication-lag artefact, not a real slowdown — patent applications typically take about 18 months to publish, so the most recent one to two years always look thinner than they eventually will. Anyone tracking this space should treat 2024 as the last complete year of data.
Sterilising and disinfecting technology (IPC class A61L) appears on 66.9% of the 175 records, making it the single busiest claim area, ahead of medicinal preparations (A61K, 40.6%) and implants and prostheses (A61F, 34.9%). Because a single patent can carry multiple IPC classes, these percentages overlap rather than sum to 100%. The heavy weighting toward A61L suggests that storage, stability and disinfection claims are the most contested part of the claim landscape, while enzyme/DNA assay claims (C12Q, 6.3%) and pest-control interactions (A01M, 4.0%) are comparatively open.
US20240131230A1, filed by L&C BIO CO., LTD. and published April 2024, covers an acellular skin substitute prepared without proteolytic enzymes or surfactants, then precision-cut for breast reconstruction implant coverage using design software and CNC machining. It is relevant to anyone developing acellularization processes that avoid enzymatic digestion, or precision-fit dermal matrix products for reconstructive surgery. Teams working on adjacent chronic wound or general graft-take indications should still review it, since the acellularization method itself may extend beyond the breast reconstruction application named in the title.
The technology composition data shows several IPC classes with comparatively few records relative to the dominant A61L and A61K classes: C12Q enzyme/DNA-based testing (6.3% of records) and A01M pest and vermin control interactions with dressings (4.0%) are the thinnest. Vascularization rate measurement and cost-effectiveness modelling for graft take, both named in the original search scope, also show fewer dedicated filings than the core sterilisation and medicinal-preparation claims. These lower-density areas are worth a closer look for anyone drafting a first claim, since less prior art typically means more room to stake defensible ground.
Research Skin Substitutes and Regenerative Wound Care in depth with Eureka
Go past this page: query the whole skin substitutes and regenerative wound care corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.